skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
NY-ESO-1/GLA-SE Vaccine ID-G305 (Code C113432)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: NY-ESO-1/GLA-SE Vaccine ID-G305

Definition: A cancer vaccine composed of a recombinant form of the tumor antigen NY-ESO-1 and glucopyranosyl lipid adjuvant (GLA)-stable emulsion (GLA-SE), with potential antineoplastic and immunomodulating activities. Upon intramuscular injection, the adjuvant portion of the NY-ESO-1/GLA-SE vaccine ID-G30 binds to toll-like receptor subtype 4 (TLR-4) expressed on dendritic cells (DCs), monocytes, macrophages and B cells. The activated DCs present the NY-ESO-1 antigen to Th1 CD4 T-lymphocytes. This leads to the induction of cytotoxic T lymphocytes (CTLs) and the killing of NY-ESO-1-expressing tumor cells. This vaccine also induces specific antibody responses and increases the production of inflammatory cytokines.

Display Name: NY-ESO-1/GLA-SE Vaccine ID-G305

Label: NY-ESO-1/GLA-SE Vaccine ID-G305

NCI Thesaurus Code: C113432 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL458226  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
NY-ESO-1/GLA-SE Vaccine ID-G305

External Source Codes: 
PDQ Closed Trial Search ID 756236
PDQ Open Trial Search ID 756236 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C113432
Contributing_Source CTRP
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom